|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Loss for the year | ||
| Recapitalization transaction expense | ||
| Share-based compensation | ||
| Depreciation and amortization | ||
| Change in fair value of warrant liabilities | ||
| Gain on remeasurement of equity interest | ||
| Finance costs | ||
| Gain on sale of subsidiary | ||
| Share of loss of equity-accounted investees | ||
| Taxation | ||
| Impairment expense | ||
| Exchange (gain) / loss | ||
| Finance income | ||
| Cash flows from (used in) operations before changes in working capital | ||
| (Increase) / Decrease in trade and other receivables | ||
| Increase / (Decrease) in trade and other payables | ||
| (Increase) / Decrease in assets held for sale | ||
| Increase / (Decrease) liabilities directly associated with the assets held for sale | ||
| Net cash used in operating activities | ||
| Development costs capitalized | ||
| Acquisitions, net of cash acquired | ||
| Capital expenditure | ||
| Purchase of shares in associates and joint ventures | ||
| Cash assumed upon consolidation through control | ||
| Proceeds from sale of investment in subsidiary | ||
| Payment of lease deposit | ||
| Interest received | ||
| Net cash used in investing activities | ||
| Proceeds from issuance of notes and warrants | ||
| Repayment of cash loan | ||
| Payment of equity and debt issuance costs | ||
| Repayments of borrowings | ||
| Interest paid | ||
| Principal payments on leases | ||
| Payments to acquire non-controlling interests | ||
| Proceeds from issuance of convertible loan notes | ||
| Repayment of convertible loan notes | ||
| Other financing activities, net | ||
| Net cash provided by financing activities | ||
| Acquisition date fair value of Higi upon consolidation | ||
| Conversion of borrowings | ||
| Acquisitions of non-controlling interests | ||
| Fair value of warrants issued in Merger | ||
| Fair value of warrants issued in connection with Loans and borrowings | ||
| Equity and debt issuance costs in accruals and provisions | ||
| Equity issued as consideration for acquisitions | ||
| Share-based compensation expense capitalized in development costs | ||
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile Net loss to net cash used in operating activities: | ||
| Non-cash interest expense, net | ||
| Non-cash restructuring and other termination benefits | ||
| Stock-based compensation | ||
| Depreciation and amortization expenses | ||
| Exchange loss / (gain) | ||
| Gain on fair value remeasurement | ||
| Premium deficiency reserve (income) / expense | ||
| Loss on settlement of warrants | ||
| Taxation | ||
| Impairment expense | ||
| Share of net loss of equity method investments | ||
| Gain on sale of subsidiary | ||
| Working capital adjustments | ||
| (Increase) / Decrease in trade and other receivables | ||
| Decrease / (Increase) in prepayments and contract assets | ||
| Increase in trade, other and claims payables | ||
| Decrease in accruals and other liabilities and due to related parties | ||
| (Decrease) / Increase in contract liabilities | ||
| Increase / (Decrease) in operating lease liabilities | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Capital expenditure | ||
| Acquisitions, net of cash acquired | ||
| Purchase of shares in equity method investments and joint ventures | ||
| Proceeds from sale of investment in subsidiary | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from issuance of notes and warrants | ||
| Proceeds from the issuance of shares | ||
| Payment of debt issuance costs | ||
| Payment of equity issuance costs | ||
| Other financing activities, net | ||
| Repayment of cash loan | ||
| Proceeds from issuance of convertible loan notes | ||
| Net cash provided by financing activities | ||
| Less: Cash and cash equivalents classified as held for sale | ||
| Net increase / (decrease) in cash and cash equivalents | ||
| Cash and cash equivalents at January 1, | ||
| Effect of movements in exchange rate on cash held | ||
| Cash and cash equivalents at December 31, | ||
| Non-cash financing and investing activities: | ||
| Issuance of Loans and borrowings upon conversion of interest | ||
| Shares issued upon settlement of warrants | ||
| Impairment expense recognized due to restructuring | ||
| Accrued and unpaid interest within Accruals and other liabilities | ||
| Fair value of warrants issued | ||
| Capital expenditures in trade payables | ||
| Fair value of Earnout liabilities issued in connection with Loans and borrowings | ||
| Conversion of borrowings | ||
| Acquisition date fair value of Higi upon consolidation | ||
| Acquisitions of non-controlling interests | ||
| Equity and debt issuance costs in Accruals and other liabilities | ||
| Equity issued as consideration for acquisitions |
Loading...
